MARKET

ITCI

ITCI

Intra-Cellular Therapies
NASDAQ
59.07
-0.53
-0.89%
After Hours: 59.42 +0.35 +0.59% 17:36 11/28 EST
OPEN
59.65
PREV CLOSE
59.60
HIGH
60.06
LOW
58.86
VOLUME
751.44K
TURNOVER
0
52 WEEK HIGH
67.05
52 WEEK LOW
42.01
MARKET CAP
5.68B
P/E (TTM)
-36.3306
1D
5D
1M
3M
1Y
5Y
S&P 500 Futures Fall In Premarket Trading; Intra-Cellular Therapies, GE HealthCare Techs Lag
U.s. Stock markets are set to open in two hours. Linde plc was up 5.3% in pre-market trading. S&p 500 futures were down 0.10%, with the dow jones down 1%. Stocks in asia were down overnight, while stocks in europe are down.
Barron‘s · 2d ago
Weekly Report: what happened at ITCI last week (1120-1124)?
Weekly Report · 2d ago
Wall Street Analysts Think Intra-Cellular (ITCI) Could Surge 33.02%: Read This Before Placing a Bet
NASDAQ · 6d ago
The Right Play On Intra-Cellular Therapies
Intra-cellular therapies, inc. Is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, caplyta, has achieved significant sales growth in the antipsychotic market. The drug is approved for the treatment of schizophrenia and bipolar depression in adults. Intra-cellular has several other early-to-mid-stage clinical programs in its pipeline.
Seeking Alpha · 11/20 16:49
Weekly Report: what happened at ITCI last week (1113-1117)?
Weekly Report · 11/20 09:26
Intra-Cellular Therapies: Statement of changes in beneficial ownership of securities
Press release · 11/15 07:44
Promising Outlook for Intra-Cellular Therapies: A Comprehensive Analysis of Financial Performance and Future Revenue Potential
TipRanks · 11/14 08:05
Intra-Cellular Therapies: Report of proposed sale of securities
Press release · 11/14 01:50
More
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402).

Webull offers Intra-Cellular Therapies Inc stock information, including NASDAQ: ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.